12. AI强化的研发和管理系统
Asia Cell & Gene Therapeutics Group Due Diligent Data Room
构建企业全流程数字化办公体系，实现行政、人事、财务、审批等核心办公场景的线上化、高效化，提升企业内部协同效率，降低管理成本。
Build a full-process digital office system for enterprises, realize the online and efficient operation of core office scenarios such as administration, human resources, finance, and approval, improve the internal collaboration efficiency of enterprises, and reduce management costs.
办公愿景：以数字化办公为基础，打造高效、合规、可追溯的企业内部管理平台
Office Vision: Based on digital office, build an efficient, compliant and traceable internal enterprise management platform.
跨越时空，整合全球人力，打破地域限制，实现分布式团队的无缝协同，为全球研发布局提供稳定、高效的远程工作支撑。
Transcend time and space, integrate global human resources, break geographical restrictions, realize seamless collaboration of distributed teams, and provide stable and efficient remote work support for global R&D layout.
平台愿景：以云技术为桥梁，整合全球优质人力，支撑企业全球化业务拓展
Platform Vision: Take cloud technology as a bridge, integrate high-quality global human resources, and support the global business expansion of enterprises.
泉生生物新药研发标准化流程化在线管理系统
• 研发流程全线上化，实现端到端可追溯
Full online R&D process, realizing end-to-end traceability.
• 标准化作业规范，降低研发试错成本
Standardized operation specifications, reducing R&D trial and error costs.
• 对接AI研发体系，提升流程运转效率
Connect with AI R&D system to improve process operation efficiency.
• 全球跨时空协同，整合优质人力资源
Global cross-time and space collaboration, integrating high-quality human resources.
Celzyva集AI技术和新药研发经验正在成功打造[人工智能全面直接作用于新药研发管理、协调、科技指挥、评价、申报等]的人工智能新药研发系统（全球包括美国发明专利申请中）。结合Celzyva的既定战略，充分利用中国在细胞新药领域的巨大成本优势，Celzyva计划通过其人工智能新药研发系统，预计在2026年四季度纳斯达克上市后，迅速建立一个具绝对竞争优势(包括规模优势)的细胞与基因治疗新药研发企业，以大规模覆盖式强势占领CGT全球市场。
By integrating advanced AI technologies with extensive experience in drug development, Celzyva is successfully developing an AI-powered drug development system in which artificial intelligence is directly and comprehensively applied across drug-development management, coordination, scientific and technical guidance, evaluation, regulatory filings, and related activities. Invention patent applications covering this system are currently being pursued globally, including in the United States.
In line with Celzyva’s established strategy and by fully leveraging China’s significant cost advantages in cell therapy drug development, Celzyva plans to deploy this AI-powered drug development system following its anticipated Nasdaq listing in the fourth quarter of 2026. The Company aims to rapidly build a cell and gene therapy (CGT) drug development enterprise with substantial competitive advantages, including advantages of scale, and to pursue broad, large-scale penetration of the global CGT market.
[人工智能新药研发系统] + [中国内地合作研发的绝对成本优势] + [细胞新药弱专利限制] = 大规模覆盖式研发管线全球申报 = 强力占领全球市场
[AI-Powered Drug Development System] + [Overwhelming Cost Advantage of Co-Development in Mainland China] + [Limited Patent Constraints on Cell Therapy Drugs] = Large-Scale, Broad-Pipeline Development & Global Regulatory Filings = Strong Global Market Penetration